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ABSTRACT
Objective: During the early phase of evaluation of
a new intervention, data exist for present practice. The
authors propose a method of constructing a fair
comparator group using these data. In this case study,
the authors use the example of external aortic root
support, a novel alternative to aortic root replacement.
Design: A matched comparison group, of similar age,
aortic size and aortic valve function to those having the
novel intervention, was constructed, by minimization,
from among patients having conventional aortic root
replacement in other hospitals during the same time
frame.
Setting: Three cardiac surgical units in England.
Patients: The first 20 patients, aged 16e58 years with
aortic root diameters of 40e54 mm, having external
support surgery were compared with 20 patients, aged
18e63 years and aortic root diameters of 38e58 mm,
who had conventional aortic root replacement,
between May 2004 and December 2009.
Interventions: A pliant external mesh sleeve,
customised by computer-aided design, encloses the
whole of the ascending aorta. The comparator group
had conventional aortic root replacement, 16 valve-
sparing and four with composite valved grafts.
Main outcome measures: Duration of
cardiopulmonary bypass (CPB), myocardial ischaemic
time, blood loss and transfusion of blood, platelets and
clotting factors.
Results: Comparing total root replacement and
customised aortic root support surgery: CPB (median
(range)) was 134 (52e316) versus 0 (0e20) min;
myocardial ischaemia 114 (41e250) versus
0 (0e0) min; 4 h blood loss was 218 (85e735) versus
50 (25e400) ml; and 9/18 had blood transfusion, 9/18
platelets and 12/18 fresh frozen plasma after root
replacement versus 1/20, 0/20 and 0/20, respectively,
for the novel surgery.
Conclusions: Avoidance or large reductions in CPB,
myocardial ischaemia and blood product usage were
achieved with the novel surgery. These data are of use
in decision analysis and health economic evaluation
and are available early in evaluation before randomised
trial data are available.
INTRODUCTION
As new technologies are proposed, they are
tested for efficacy and safety.1 Where there is a
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ARTICLE SUMMARY
Article focus
- A novel comparative research method used
existing data to derive a comparison group in
the pre-randomised controlled trial phase of
evaluation of a new technology.
- A case study in aortic root surgery is described.
Comparison was made of the perioperative
burden of care between root replacement and
a novel tissue conserving approach to reducing
the risk of dissection in Marfan syndrome.
Key messages
- Existing data, where available, should be used
in decision analysis and health economic
evaluation.
- Before randomised trials can be completed and
reported, there may be available data to allow
reliable estimates of differences between surgical
approaches to the same clinical problem.
Strengths and limitations of this study
- Limitations are that the allocation was not
randomised and the comparison data were not
collected prospectively.
- A strength is that available clinical data acquired
while different surgical strategies were employed
at different institutions during the same time
frame allow rigorous and timely comparison to
be made at an early stage in the introduction of
a novel technology.
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pre-existing technology, comparative evaluation should
be routine so that when a new technology is demon-
strably superior, in terms of effectiveness and cost-effec-
tiveness, it should replace existing practice. It appears
self-evident that the competing technologies should be
subjected to a ‘fair test’,2 and the fairest test is unbiased
allocation in a randomised controlled trial (RCT). RCTs
have been infrequently used in evaluation of surgery to
the point that some dismiss them as just too difficult to
countenance and thus inappropriateda ‘square peg in
a round hole’.3 Too often this attitude provides an excuse
to rely solely on case series, analysed retrospectively, and
riven with flaws.4 UK surgeons are aware of the need to
recruit into surgical trials5 but when it is randomisation
that appears to be the insurmountable obstacle it is
important not to forget the second word in RCT:
‘controlled’. To have some comparative data is surely
better than having none in evaluating technology.
The case in point is the evaluation of a new technology
to reduce the risk of aortic dissection in people with
Marfan syndrome, which is by far the most important
life-threatening consequence of the disease.6e8 The new
technology involves the use of modern digital imaging
and computer-aided design (called CAD modelling) to
manufacture a pliant but adequately strong external
support, made of a porous mesh, custom made to fit the
individual’s ascending aorta from the left ventricle to the
proximal aortic arch.9 It is available as an alternative to
total aortic root replacement.10 11
Total replacement of the ascending aorta and the
aortic valve, a major, radical and ablative operation,
became established practice from about 25 years ago.12
Based on comparison with historical life expectancy
data, it was convincingly effective in increasing the life-
span of people with Marfan syndrome.13 As the surgical
risk reduced over time, root replacement became the
routine pre-emptive strategy,14 but while the operative
risk diminished, mandatory life long anticoagulation,
sometimes from a young age, became a major concern.
Incorporation of a tissue (rather than a mechanical)
valve removed the need for anticoagulation15 but intro-
duced the problem of failing tissue valves, typically by
about 15 years.
Technically exacting methods of conserving the
patient’s own valve leaflets were the next develop-
ment.16 17 Valve replacement and valve conserving
strategies have been compared in a systematic review of
1385 patients in 11 surgical cohort studies published
from 1999 to 2009.18 More than a quarter of patients had
further aortic valve surgery within 20 years of a valve-
sparing operation and more than half had further
complex aortic root surgery during their lifetimes. The
overall likelihood of a valve-related event (further aortic
surgery, thromboembolism or endocarditis) for all forms
of root replacement was 1.5% per annum.18 These
patients are operated on at an average age of 35 and
might hope to live at least as long afterwards. By then the
cumulative lifetime risk of serious valve-related events
associated with aortic root replacement reaches 50%d
that is to say ‘even odds’. It is easy to overlook the real
implication of data provided in low percentage rates per
annum.19
The non-ablative option in which all of the aorta, the
aortic valve and the functioning blood/endothelial
interface are conserved, employing modern technology,
is now available,9 but there have been to date real
obstacles to a randomised trial.
1. The detrimental events following aortic root replace-
ment with a composite mechanical valved graft, tissue
valve replacement and valve-sparing surgery occur
over a long time frame and are manifest at different
points in time.
2. Marfan syndrome has a prevalence of 2e3 patients
per 100 000.20 Any prospective study might take an
unconscionable time to accrue sufficient patients into
an adequately powered trial.
3. Ablative root replacement is usually deferred until
there is proven progression but the conservative
external support operation is intended to halt the
local process of dilatation. Relatively few patients are
similarly eligible for both operations at the same time
point so a trial design might involve the indirect
comparison of external support versus a continued
watch and wait policy.
4. Existing practice is regarded as conventional manage-
ment, while external support is framed clearly as an
innovation.11 There is as yet no sense of a level
playing field for evaluation, so the criterion of
equipoise, required for a randomised trial, is not
attained.
It is worth noting that it is not generally the innovators
who are reluctant to subject their innovation to a rand-
omised trial and the reason is a simple and self-evident
one. The innovator stands to gain up to a 50% share of
practice during evaluation in an RCT, while the estab-
lished method can only lose ‘market share’. Accrual of
evidence will inevitably take many years and many
operations, irrespective of whether the evidence comes
from an RCT or a cohort study.11
Meanwhile, there are important question that can be
answered from existing data.
1. Cardiopulmonary bypass (CPB) is essential in all
aortic root replacement operations but is routinely
avoided with the tissue conserving external aortic root
support (EARS) operation. This difference can be
quantified and its clinical and cost implications can
be estimated from existing data.
2. Transfusion of blood and blood products is common
with aortic root replacement due to the nature of the
surgery and the detrimental effects of CPB on the
coagulation system. The difference in use of blood
products can be quantified from existing data and the
clinical consequences estimated.
3. The coronary arteries must be disconnected for
a period of an hour or more for root replacement
operations.21 The deleterious effects are ameliorated
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by cooling and hyperkalaemic arrest but it is a hazard
that is routinely avoided with EARS.
4. Opening the aorta provides an opportunity for air
and particulate embolisation and a consequent risk of
stroke. In the aortic root support surgery, the aorta is
never opened.
All four are differences by intent between the root
replacement and root conserving strategies. It does not
require an RCT to discover that these are different; it is
an evident effect of the surgical approach. Putting
bounds on how great or small the differences might be
and their consequences can be estimated on existing
data provided careful comparison of like with like is
made.
METHODS
Surgical units known to have expertise in aortic root
surgery for Marfan syndrome were invited to collaborate
in this study. The National Research Ethics Service
advised that the study did not require ethical approval
under the NHS Research Governance Arrangements
(letter dated: 30 June 2009). The project was registered
with the local audit departments, and all data were
collected and verified by a single member of the Cardiac
Surgical staff in each hospital from prospectively main-
tained databases and retrospective notes review. The
centres were asked to identify all patients undergoing
elective aortic root replacement for Marfan syndrome
from May 2004 to December 2009, which was the period
during which the first 20 patients received an EARS at
the Royal Brompton Hospital.21
The centres were asked to record on a standardised
case report form (CRF) for the patients who had
undergone elective aortic root replacement only
preoperative characteristics, namely date of birth, sex,
date of operation, operation performed (composite
valved graft aortic root replacement or valve-sparing
aortic root replacement), the latest preoperative aortic
root dimension, whether echocardiography, CT or MRI
were used for this measurement, and the grade of any
aortic regurgitation. No intraoperative or outcome data
were requested at this stage. The CRFs were sent to the
Clinical Trials and Evaluation Unit (CTEU) at the Royal
Brompton Hospital without patient identifiers and
were checked (BL) to ensure that there were no missing
data and that there was no outcome information
recorded.
The date of birth, sex, preoperative aortic root diam-
eter, degree of any aortic regurgitation and the date of
elective surgery for the first 20 patients having the novel
operation of aortic root support at the Royal Brompton
Hospital were obtained by the CTEU. In order to select
a group of 20 patients that matched them, with respect
to age, sex, aortic root size and degree of aortic regur-
gitation, we applied the principles of minimisation.22e24
Only after this process was completed were the intra-
operative and immediate postoperative details obtained:
date of discharge from hospital, operative start and end
times, bypass time, ischaemic time, chest tube drainage
up to 4 and 12 h, blood product usage (including red
cells, platelets and fresh frozen plasma) and oral anti-
coagulant usage for the elective aortic root replacement
cohort (AR and RA) and for the EARS cohort (KMJC).
The details were recorded on a standardised CRF. Again
no patient identifiers were recorded or sent to the
CTEU. The CTEU checked that there were no missing
data prior to analysis. Data analysis was then performed
in a research unit (CORU) remote from any of the three
clinical sites (SC and TT).
Data analysis
The analysis plan was prepared (TT and SC) prior to any
data being received or analysed. The elective aortic root
replacement cohort were compared with the EARS
cohort with respect to age at operation, preoperative
aortic diameter, operation time, bypass time, cross-clamp
time, postoperative days in hospital, chest tube drainage
at 4 and 12 h postoperative and type and amount of
blood products and oral anticoagulants given.
The purpose of the analysis was to quantify the burden
of the interventions in the different operative strategies.
It was not appropriate to apply hypothesis testing statis-
tical methods to bypass or ischaemic time since these
were inherent in the surgical strategy. Hospital stay,
blood loss and blood product usage were the outcomes
of these different strategies and these can be compared
meaningfully.
RESULTS
Comparator case selection
Queen Elizabeth Hospital, Birmingham, UK, and Guys
and St Thomas’ Hospital, London, UK, collaborated in
the study and a team member at each (AR in
Birmingham and RA at St Thomas’ Hospital) were the
only point of contact with the CTEU (BL). Data on
a total of 33 anonymous patients, identified as having
root replacement for Marfan syndrome during the
specified time frame, were sent by the two other cardiac
units (figure 1). Four patients had repeat surgery and in
two, surgery involved the arch or descending aorta; they
would not have been candidates for EARS and were
excluded. The external root support patients, by
protocol, had aortic root diameters of 4e5.5 cm and no
more than grade 1 (trivial) aortic regurgitation. Four
patients who clearly fell outside those criteria were
excluded. For 23 remaining patients, the age range was
16e73 years and aortic diameters of 24e66 mm. To
minimise imbalance22 between the groups in terms of
age and aortic root dimension, three further exclusions
were made so that 20 patients remained who provided
the best match with the 20 patients in the EARS
cohort with regard to age, aortic dimension and aortic
regurgitation.
Of these 20 patients, four had composite valved grafts
(ages 30, 46, 53 and 63 years) and 16 had valve-sparing
operations. There was a poor match for sex: 14 males in
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the novel surgery group and eight males in the
comparison group. There were insufficient patients to
improve further on matching for sex so the method was
only partially successful due (at least in part) to an
insufficiently large pool of patients from which to
draw an ideal comparison group. The age and preop-
erative aortic dimension of each cohort are shown for
all individuals in figure 2 and summary statistics are in
table 1.
Operative data
The operation time, bypass time, ischaemic time, post-
operative days in hospital and chest tube drainage up
to 4 and 12 h after surgery are shown in table 2 for both
groups of patients. The median operation time for the
novel surgery group (table 2 and figure 3) was 2.5 h
compared with 4 h for root replacement patients. In the
novel surgery group, the first patient had a brief period
(20 min) of CPB but thereafter bypass was not used in
any patient and all were operated upon without any
myocardial ischaemia. In comparison, the median time
on CPB for root replacement patients was 134 min and
their median ischaemic time was 114 min. Postoperative
stay in hospital was similar in both groups (table 2) and
when tested was not significantly different
(ManneWhitney U test).
The chest tube drainage for conservative surgery was
less than that for root replacement (table 2 and figure 3)
(p<0.02, ManneWhitney U test). Table 3 shows the
number of patients and the nature of blood products.
One of the patients in the novel surgery group was given
a single unit red cell transfusion but they received no
other blood products. In the comparison group, 9/18
patients (two not ascertained) were given red cell
transfusions (p¼0.002, Fisher’s test), 9/18 platelets and
12/18 fresh frozen plasma (p<0.001, Fisher’s test) (see
table 3 and legend). Five of the patients having root
replacement were prescribed oral anticoagulants, which
will be mandatory for life for those with a mechanical
heart valve.
DISCUSSION
There are two distinct elements to this discussion. First,
we must consider the validity, limitations and lessons
learnt about the method, which to the best of our
knowledge has a degree of innovation. Only then is it
useful to consider the reliability and value of what has
been learnt in comparing the new technology of aortic
root conservation and support with the established
aortic root replacement surgery.
Considering its limitations, this novel method of
comparison lacks two of the essential elements of an
RCT: patients were not allocated by randomisation and
the study was not prospective. On the other hand, in
RCTs of surgery, blinding is nearly always impossible so
bias in the delivery of potentially compensating forms of
care, and bias in collection and recording of data,
cannot be excluded and so a real difference in outcome
may be diminished or not evident. In the present study,
the 20 patients who had root replacement were among
a very large number of patients having all forms of
cardiac surgery. The teams could not know that their
routinely collected clinical data would be used for
a future comparison with a competing technology. Thus,
the use of previously obtained patient data to derive
a group for comparison has the incidental advantage
that those recording those data had no knowledge of
Figure 2 Comparison between the external aortic root
support (EARS) patients (boxes) and comparison group
(circles) for (A) age at operation and (B) aortic diameter
preoperation. The vertical bars denote the medians and the
boxes indicate the IQRs.
Table 1 Comparison of the external aortic root support
(EARS) patients (N¼20) and the comparison group (N¼20)
with respect to age at operation and aortic diameter
preoperation (millimetres)
Mean Median IQR Range
Age at operation (years)
EARS 33 33 26e39 16e58
Comparison 37 35 27e43 18e63
Aortic diameter (mm)
EARS 46 47 43e48 40e54
Comparison 48 48.5 44e52 38e58
Figure 1 Flow chart for control group. EARS, external aortic
root support.
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the research question and this may confer a useful
advantage.
Our objective in this study was to find a contempora-
neous group of patients, operated on by surgeons
performing conventional root replacement, uncontami-
nated by involvement in the development of the new
customised external root support. The construction of
the comparison group employed the concept of mini-
misation as a means of ensuring that important variables
were as similar as possible in the two groups. Critics of
minimisation argue that the opportunity for bias cannot
be excluded because the likely allocation of the next
patient may be predictable from knowledge of existing
mismatches between the groups.24 This problem does
not exist, at least not in this precise form, when patients
are selected from existing data but the opportunity
certainly does for the investigators to select patients in
whom the outcome is already known. For that reason, we
fastidiously avoided any knowledge of the outcome of
these patients being accessible to those involved in the
process of deriving the comparison group.
A further limitation in the present study was that the
pool of patients for comparison was not large enough to
match as completely as we would have liked and failed to
achieve balance on sex mix. Also the root replacement
group included both those whose root replacement
spared or replaced the valve. An ideal study would have
representative numbers of these two operations for
comparison (composite root replacement with a tissue
valve is likely to be infrequent in this age group). We had
approached other teams who declined sharing data on
this occasion. However, the differences in the outcomes
were so large that in this instance we do not believe
further matching would have altered the conclusion.
The method includes another useful feature. It shares
the principles of an expertise-based study.25 In drug
trials, the patient is handed identically labelled packs of
pills and no therapeutic expertise is involved but the
expertise of the deliverer of care is an important
consideration in non-pharmacological interventions.26
This applies in all technical interventions, in physical
interventions such as physiotherapy and in psycho-
therapy; in all these examples, the person providing care
is an important element in the potential effectiveness of
that care. In the present study, surgeons were not asked
to perform operations by random allocation but had
Table 2 Comparison of the external aortic root support (EARS) patients and the comparison group with respect to procedural
data
Median IQR Range
Operation time (min)
EARS (N¼20) 148 136e163 125e415
Comparison (N¼19*) 240 204e269 150e414
Bypass time (min)
EARS (N¼20) 0 0e0 0e20y
Comparison (N¼20) 134 117e146 52e316
Ischaemic time (min)
EARS (N¼20) 0 0e0 0e0
Comparison (N¼20) 114 91e127 41e250
Postoperative days in hospital
EARS (N¼20) 6 5e7 4e16
Comparison (N¼20) 7 6e8 4e17
Chest tube drainage up to 4 h after surgery (ml)
EARS (N¼20) 50 50e100 25e400
Comparison (N¼18*) 230 155e370 85e735
Chest tube drainage up to 12 h after surgery (ml)
EARS (N¼20) 120 75e200 25e925
Comparison (N¼18*) 385 326e688 200e1010
*Missing data for one or more patients.
yNote that for the EARS group, cardiopulmonary bypass was used for 20 min in the first patient only and none had any interruption to coronary
blood flow.
Figure 3 Comparison between the external aortic root
support (EARS) patients (boxes) and comparison group
(circles) of (A) duration of surgery in minutes, (B) blood loss in
the first 4 h postoperation in millilitres and (C) blood loss in the
first 12 h postoperation in millilitres. The grey boxes indicate
the interquartile range.
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already performed their preferred operation in which
they were practiced and confident, a feature shared with
an expertise-based randomised trial.25
There is a recognised problem in achieving sufficient
numbers for conventional study designs in rare
diseases.27 It is made more difficult if important
outcome measures and adverse events accrue over many
years. For example, native valve failure in valve-sparing
surgery is important even after 10e15 years of perfect
function. A devastating thromboembolic event in the
first year after surgery, with residual disability, will
dominate the outcome even if there are no subsequent
events. Patients will weigh these risks differently as they
make choices and they are influenced by both the weight
put on them by doctors giving advice and whether they
appear imminent or remote.28 Marfan syndrome is
uncommon and the number of patients meeting the
clinical criteria, such that they are candidates for either
operation, is small but, in uncommon diseases, ‘some
unbiased evidence is clearly better than none’.27
We believe that this approach to evaluation of a new
technology may be generalisable. New interventional
procedures are first introduced in one or a few centres
while existing practice continues elsewhere. Many of
these patients would have been candidates for the new as
well the existing procedure, which they have received. By
collecting initially only preoperative variables and by
placing this process in the hands of the clinical trials unit
(Royal Brompton Hospital, CTEU), we ensured that the
selection was made only on explicit pre-stated criteria.
To generalise the method, the case selection would need
to be from as large a pool as possible and carried out by
completely uninvolved and impartial investigators,
without access to the outcome data at the time that the
case selection is being made. If this method is to be
replicated, it should be considered mandatory that the
process be put in the hands of entirely neutral meth-
odologists, blind to outcomes and with no vested interest
in the answer to the research question.
To turn to what we have learnt about the specific
subject of our research, we have previously drawn
a comparison between the first 20 patients having EARS
so the findings presented here are not completely new.21
However, the comparison in the earlier study was with 28
patients having root replacement in the same hospital,
not all with Marfans syndrome and who were not
candidates for the EARS surgery. The comparison group
reported here are non-overlapping, operated on during
the same time frame, in other hospitals where external
support was not available. All 40 patients were eligible
for replacement or aortic root conserving surgery.
Although the findings are not surprising, they provide
a much better estimate of real differences than we could
achieve in our previous study.21
Avoidance of CPB and reduction in transfusion of
blood products have been consistent objectives in
reducing the detrimental effects of cardiac surgery. In
this study, CPB was used as a safety measure in the first
patient having aortic root support29 but was not used
thereafter. One patient had a single unit blood trans-
fusion. In addition, operative times were shorter even
during the learning period for this new operation. There
was no interruption to normal physiological myocardial
perfusion through the coronary arteries. In contrast,
interrupting coronary perfusion, while the myocardium
is protected by hypothermic hyperkalaemic cardiac
arrest, is mandatory for root replacement and was used
from 40 min to up to 4 h, with a median approaching
2 h. These perioperative benefits were anticipated from
a theoretical standpoint, being inherent in the non-
ablative nature of the surgery, but they cannot be
assumed to be consistently achievable. Formal quantifi-
cation is essential if the data are to be used in decision
analysis and health economic evaluation. There are
potentially very large differences in the burden of care,
costs of care and the potential for harm.
These differences did not translate into reduced
hospital stay in this study. Postoperative stay is likely to be
influenced by the chest wall incision, hitherto a signifier
of major cardiac surgery. Median sternotomy does not
require hospital stay beyond the initial recovery period,
say the first night, and much shorter stay is an attainable
goal in the future.
None of the existing forms of aortic root surgery,
whether they involve mechanical or tissue valve replace-
ment, or valve-sparing surgery, offers a perfect or perma-
nent solution for people with Marfan syndrome.11 30 The
first test of effectiveness of this novel technology should
be that it is not inferior to the alternatives in terms of the
combined lifetime risks of aortic dissection, other Marfan-
related cardiovascular events, arterial thromboembolism,
anticoagulant-related bleeding, endocarditis and reoper-
ation. Table 4 summarises some of these from a theoret-
ical standpoint and suggests that, for a checklist of
preoperative and lifetime hazards, external support has
a favourable profile.
The ultimate test of external support is whether it will
prevent dissection in the ascending aorta, which is the
only achievable objective of surgery. Monitoring of aortic
Table 3 Comparison of how many external aortic root
support (EARS) patients and how many patients in the
comparison group had a red cell, platelet or fresh frozen
plasma (FFP) transfusion
Transfusion
product
Number of patients
EARS group
(N[20)
Comparison
group (N[18)*
Red cell 1 9
Platelet 0 9
FFP 0 12
Note that of the EARS group, 1/20 patients received a single unit
red cell transfusion. Of the comparison group (*data missing for two
patients), 9/18 were recorded as receiving red cell transfusions
(mean 2.0 units per transfused patient), 9/18 received platelet
transfusions (mean 1.6 units per transfused patient) and 12/18
received FFP transfusions (mean 4.8 units per transfused patient).
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size by echo, and deferring surgery until agreed size
criteria are reached, is well-established practice. While
the association between dissection and larger aortic size is
highly significant, dissection can occur in
Marfan syndrome in a relatively small aorta.31 32 While
this intimately applied external support might not
completely obviate that risk, it seems a reasonable
expectation that it will be substantially reduced. It is also
probable that if dissection should occur, its consequences
will be less severe. There is evidence from an animal study
(as yet unpublished) that the mesh of the supporting
sleeve becomes incorporated in the aortic adventitia and
increases the stress tolerance of the arterial wall. Knowl-
edge of the surgical pathology of aortic dissection
encourages us to think that this form of external support
will confer these benefitsdbut nothing other than long-
term follow-up will answer those questions.
It should be noted that this computer-designed and
customised support, manufactured from a pliant and
porous mesh, is very different to wrapping the aorta
with the stiff graft material as has previously been
proposed.33 34
It has become an entrenched belief that excision of
the aorta is an essential component of Marfan root
surgery, and reservations about the external support
have drawn attention to the fact that the aortic tissue
remains and yet the extent of excision in root replace-
ment does not routinely include the entire ascending
aorta. For surgeons who perform this surgery without
circulatory arrest, the safe placement of an aortic cross-
clamp, proximal to the brachiocephalic artery with
sufficient clearance for the distal suture line, mandates
that at least a couple of centimetres of the ascending
aorta remains. Surgeons who routinely perform an
‘open’ distal anastamosis achieve more complete
replacement of the aortic root and a more technically
satisfactory distal anastamosis, at the price of 10e15 min
of total circulatory arrest.35e37 The external mesh
supports the aorta to beyond the brachiocephalic artery
without the need for any circulatory arrest, obviating this
technical debate.
Consideration of these technical details highlights
a further consideration in the comparison between valve-
sparing root replacement and external support of the
existing of aorta and valve. Intraoperative skill and deci-
sion making are to a large extent replaced by preopera-
tive measurement and device manufacture, moving the
intervention from ‘workmanship of risk’ towards the
‘workmanship of certainty’.38 This concept is well
understood in design and production of wooden furni-
ture, which ranges from unique craft made objects to
those manufactured to precise and reproducible specifi-
cations. While the uniqueness of wooden carving is part
of its charm and value, to deliberately retain hazard and
uncertainty in a surgical operation, when there is an
engineered alternative, would surely be a mistake.
The best evidence for effectiveness and cost-effective-
ness would ideally be obtained from direct comparison in
a RCT,5 but these first 20 operations were performed by
one surgeon in a single institution as part of formal early
phase evaluation. Randomisation is not considered
possible until the operation is shown to be achieved
consistently.1 All 40 patients in this study would have been
candidates for either external support or root replace-
ment. Even so, it must be recognised that the cardiologist
and/or the patient might have expressed a firm prefer-
ence for one or the other, thus blocking random alloca-
tion. Not all prospective patients who are candidates for
root replacement could be randomly allocated to
external support or vice versa. The indications for
external support and for root replacement overlap but
they have important differences. For aortic root replace-
ment, there is no upper size limit and it is not precluded
by any severity of aortic regurgitation, whereas at this
stage in the evaluation of external support, an already
established large aneurysm or aortic regurgitation (more
than trivial) would be a contraindication.
An RCT has the potential to provide the definitive
answer to one well framed question but there are many
other things we need to know in evaluating competing
technologies. While considering the data required for
health economic evaluation,39 we found that a published
decision analysis was severely hampered by lack of data
on probability of dissection-free survival of patients with
Marfan syndrome.40 Bentall’s first patient to have total
root replacement as an unplanned procedure had
a massive aneurysm, with walls ‘so thin that the blood
could be seen eddying within’.41 The most likely natural
outcome was death from dissection or rupture of the
aortic wall and the ‘number needed to treat’ to save that
patient’s life was, in all probability, one but the number
needed to treat (NNT) to save a single life gets larger as
Table 4 The relative merits of four approaches to surgical management of the aortic root in Marfan syndrome to reduce the
risk of death due to dissection
Hazard Bentall mechanical Bentall tissue Valve sparing External support
Cardiopulmonary bypass + + + 
Blood products + + + 
Thrombembolic risk +   
Anticoagulation +   
Endocarditis + +  
Reoperation for valve failure  + +/ ?
The symbols + or  represent a simple dichotomy where + indicates an inherent hazard whether inevitable such as the need for
cardiopulmonary bypass or a serious but uncommon risk such as endocarditis.
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the threshold for any intervention lowers. For example,
in carotid endarterectomy, NNT is six for 70%e99%
carotid stenosis and rises to 24 for 50%e69% carotid
stenosisi based on randomised trials. As surgery has
become safer, we have progressively lowered the aortic
size at which surgery is performed electively in Marfan
syndrome. Some patients, perhaps many, may have lived
without progressive dilatation of dissection, and,
although how many and who they would have been can
never be known, for those patients their operation
availed them nothing. Harms become an ever more
important part of the equation. Each element of the
decision-making process should be updated as practice
changes.39 Where contemporary data already exist,
without the need for an RCT, it makes sense to use them.
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